MeiraGTx (NASDAQ:MGTX) Stock Price Down 6.2% – Time to Sell?

Posted by George Bondi on Oct 23rd, 2026

MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report)’s stock price traded down 6.2% during trading on Friday. The company traded as low as $9.16 and last traded at $9.1620. Approximately 133,704 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 752,458 shares. The stock had previously closed at $9.77.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MGTX shares. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of MeiraGTx in a report on Wednesday, July 8th. Wall Street Zen lowered MeiraGTx from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Weiss Ratings raised MeiraGTx from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. The Goldman Sachs Group began coverage on MeiraGTx in a research note on Thursday, September 24th. They issued a “neutral” rating and a $16.00 target price for the company. Finally, Royal Bank Of Canada lifted their target price on MeiraGTx from $26.00 to $27.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, MeiraGTx presently has an average rating of “Moderate Buy” and an average target price of $24.00.

View Our Latest Analysis on MeiraGTx

MeiraGTx Stock Down 5.5%

The company has a quick ratio of 3.76, a current ratio of 3.76 and a debt-to-equity ratio of 0.46. The firm has a market cap of $886.64 million, a PE ratio of 13.01 and a beta of 1.35. The stock has a 50-day simple moving average of $12.27 and a two-hundred day simple moving average of $11.41.

MeiraGTx (NASDAQ:MGTX – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $2.17. The firm had revenue of $321.43 million during the quarter, compared to the consensus estimate of $0.70 million. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%. Analysts expect that MeiraGTx Holdings PLC will post 0.30 earnings per share for the current year.

Insider Buying and Selling

In other MeiraGTx news, CEO Alexandria Forbes sold 62,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $13.86, for a total transaction of $859,320.00. Following the transaction, the chief executive officer owned 1,325,695 shares in the company, valued at approximately $18,374,132.70. This represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stuart Naylor sold 27,659 shares of the stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $10.64, for a total value of $294,291.76. Following the completion of the transaction, the insider directly owned 613,187 shares of the company’s stock, valued at $6,524,309.68. This represents a 4.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 145,659 shares of company stock valued at $1,710,812 over the last three months. Corporate insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On MeiraGTx

A number of institutional investors and hedge funds have recently made changes to their positions in MGTX. Squarepoint Ops LLC increased its holdings in shares of MeiraGTx by 773.9% during the second quarter. Squarepoint Ops LLC now owns 162,412 shares of the company’s stock valued at $2,194,000 after acquiring an additional 143,828 shares in the last quarter. Johnson & Johnson purchased a new position in shares of MeiraGTx in the 2nd quarter worth about $89,720,775. Tocqueville Asset Management L.P. bought a new position in MeiraGTx in the 2nd quarter worth about $1,050,000. Sei Investments Co. bought a new position in MeiraGTx in the 1st quarter worth about $863,000. Finally, Bank of New York Mellon Corp purchased a new stake in MeiraGTx during the 2nd quarter valued at about $1,869,000. Institutional investors own 67.48% of the company’s stock.

About MeiraGTx

(Get Free Report)

MeiraGTx Holdings plc is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes to targeted tissues and address the underlying causes of disease.

Its research and development activities have focused primarily on disorders of the central nervous system, including neurodegenerative diseases, as well as retinal and salivary-gland conditions.